Work

Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion

Year: 2026
Type: article
Abstract: Acute myocardial infarction (AMI) causes heart failure and mortality, driven by ischemia/reperfusion (I/R) injury and CD47/Signal regulator protein α (SIRPα)-impaired efferocytosis that together sustain tissue damage. Endogenous plasma small extracellular vesicles (P-EVs) offer an endogenous, multifunctional option, yet their cardioprotective efficacy is limited by low cardiac accumulation. Herein, a nanosystem (SαV-DAb) was developed by functionalizing SIRPα-variant-overexpressing nanovesicles (SαV) with dual antibodies (DAb) against CD42b (platelet marker) and CD63 (EV marker) via a reactive oxygen species (ROS)-cleavable linkage. This configuration allows the nanovesicles to hitchhike on circulating platelets for targeted delivery to the ischemic heart, while simultaneously capturing and enriching protective circulating P-EVs in the lesion. SαV could bind to CD47, avoiding the SIRPα activation on macrophages and promoting efferocytosis. SαV-DAb demonstrated significantly enhanced cardiac accumulation and promoted targeted delivery of P-EVs to the ischemic myocardium. Treatment with SαV-DAb elicited a coordinated therapeutic response, including anti-apoptosis, pro-angiogenesis, and pro-efferocytosis, ultimately leading to attenuated ventricular fibrosis and improved systolic function after I/R injury, with no observable toxicity. This strategy simplifies the preparation workflow by avoiding prior isolation of PLTs and protective vesicles, and provides a conceptual framework for endogenous-system-based nanomedicine in cardiac repair.
Language: English
Open Access status: gold
Estimated APC paid: $6,730
OpenAlex ID: W7234035062
FWCI:
Cites: 42
Cited by:
Related to: 10